News Posts List
MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens
07/01/2010
Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality. Characterization of microRNA (miRNA) expression of RCC will help disclose new pathogenic pathways in tumourigenesis and progression and may lead to the development of molecular biomarkers and target-specific therapies for diagnosis, prognostication and treatment.
Minimizing Blood Flow Interruption During Surgery Lowers Kidney Disease Risk
07/01/2010
Interrupting blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease, according to a new study.
Robust Annual Growth in the Renal Cell Carcinoma Drug Market
06/30/2010
The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma reveal that significant uptake of the angiogenesis inhibitor Votrient/Patorma will be driven by its use in treating advanced renal cell carcinoma, particularly in the first-line setting. As a result, Votrient/Patorma will become the market leader and will garner sales of nearly $630 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Father's Day offers a chance to celebrate for a grieving John McDonald
06/30/2010
McDonald did it for his father, Jack, who died on June 14 after an eight-month ordeal with liver and kidney cancer.
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
06/30/2010
This is an open-label, multi-center study to evaluate the safety of RAD001 in Chinese patients with metastatic renal cell cancer who are intolerant of or have progressed despite treatment with vascular endothelial growth factor (VEGF)-targeted therapies.
Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis
06/30/2010
TNF antagonist induced psoriasis is a well–described adverse event without any known predisposing risk factors.
The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma
06/30/2010
Patients with a family history of ccRCC have pathological and clinical outcomes similar to patients with sporadic ccRCC.
Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy
06/30/2010
Carbonic anhydrase IX is a promising target for improving diagnosis, prognosis, and therapy of renal cell carcinoma (RCC) patients.
Predicting Occult Multifocality of Renal Cell Carcinoma
06/30/2010
The data suggest that occult multifocal RCC is more frequently associated with small (2–4 cm) renal lesions.
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
06/30/2010
This review will summarize what is known about the fundamental biology that underlies clear cell RCC,
News Feed